Curculigo orchioides Gaertn (family Hypoxidaceae, also known as black or kali musli), is an endangered medicinal plant used for diverse medicinal purposes including impotency, aphrodisiac, diuretic, tonic, jaundice, and skin ailments. Phytochemical investigations of rhizomes revealed the presence of a novel phenolic glycoside, curculigoside, triterpenoid, saponins, flavones, cellulose, hemicellulose, and calcium oxalate. We developed a novel extract of Curculigo orchioides (Blamus™, standardized to 30% curculigosides) and assessed its dose‐and time‐dependent efficacy (0, 10, 25 and 50 mg/kg body weight p.o.) on body weight, serum free and total testosterone levels in male rats (200–230 grams; n = 6) over a period of 28 days. Blamus™ didn't cause any marked elevation in serum free testosterone levels at either10 or 25 mg/kg body weight doses, however, a 50 mg/kg body weight dose of Blamus™ induced a significant increase in serum free testosterone level (*p < 0.0001). However, no significant increases were observed in serum total testosterone levels at 0, 10, 25 or 50 mg/kg body weight doses of Blamus™. Extensive testicular histopathological analyses including investigations on the seminiferous tubules, spermatogenesis, sperm cell morphology, Leydig cells and Sertoli cells following treatment with either 0, 10, 25 or 50 mg/kg body weight doses of Blamus™ demonstrated dose‐dependent improvement in structural integrity. Furthermore, no significant changes were observed in serum SGOT, SGPT, BUN and creatinine levels following treatment with any of the given doses, which demonstrated its safety profiles. These data demonstrated that Blamus™ may serve as a safe and novel, natural testosterone booster and provide broad spectrum application is sports nutrition, muscle building and exercise pathophysiology.Support or Funding InformationThis Project was Funded by Cepham Inc., Piscataway, NJThis abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.
Objectives NHLBI announced that anemia is one of the most common blood disorders, which affects more than 3 million Americans, while the Global Burden of Disease 2016 reported that anemia affects 1.93 billion people worldwide. Anemia is associated with chronic inflammatory conditions and autoimmune disorders. Hemorrhagic anemia results in substantial loss of blood with significant alterations in all blood parameters, including reduced iron. Another type of anemia is chronic anemia syndrome, which is a comprised of disorders in conjunction with chronic inflammation induced by an escalated anaerobic/acidic environment inducing a defensive expenditure of alkalinizing buffers in hemoglobin (i.e., histidine), to prevent a dangerous lowering of blood pH. Subsequently, iron is cleaved from heme groups, and transferred out of blood circulation into other organs, like the liver, appearing to be IDA, where excessive accumulation can lead to hemochromatosis, aka ‘iron overload anemia’. An orally consumed liquid iron-free VMP35 Multi-nutrient complex exhibited to restore iron-dependent hemoglobin to RBCs. Methods A randomized controlled one-way cross-over clinical investigation was conducted in 38 subjects (age: 12–82) to assess the rate of absorption and effects on blood following administration of a VMP35, a non-iron containing liquid nutraceutical supplement. After taking a baseline blood sample at 0 min, subjects consumed and held in the mouth for 30 seconds, either placebo or VMP35 (30 ml) after which blood was taken at 5 min and/or 30 min. Changes in peripheral blood smears were evaluated using live blood cell imaging with phase contrast microscopy. Furthermore, three case studies were conducted. Results VMP35 caused remarkable changes in the blood including morphological, hematological (including restoration of hemoglobin) and rheological changes following 5 min of administration, which sustained for at least 30 min. Results of the three case studies were very encouraging. Conclusions VMP35 restored the blood properties including restoring iron-dependent hemoglobin and potential benefits for subjects with compromised digestive systems without any adverse events. Three case studies provided strong confirmation of these therapeutic benefits to promote hematological integrity and rheology. Funding Sources VNI Inc, Lederach, PA, funded this study.
Objectives Global Burden of Disease 2016 (GBD 2016) reported that Iron Deficiency Anemia (IDA) is the leading cause of anemia, which affect 1.93 billion people worldwide. Anemia is intricately linked to chronic inflammation, chronic kidney disease, gastrointestinal and gynecological malignancies, and autoimmune disorders. Hemorrhagic anemia results in substantial loss of blood which causes significant alterations in all blood parameters, including reduced iron. The other type of non-genetic anemia is chronic anemia syndrome (CAS), which is caused by an increasing anaerobic/acidic environment that forces a defensive expenditure of alkalinizing buffers in hemoglobin, releasing iron and leading to lowering of blood pH. The result is the initiation of a sequel of chronic inflammatory events. Initially, iron cleaved from heme groups is transferred into other vital organs including hepatic tissues, appearing to be IDA. This process results in excessive tissue iron accumulation leading to hemochromatosis, aka ‘iron overload anemia’. Ultimately, tissue iron saturation results in downregulation of tissue storage and a buildup in blood plasma. A novel iron-free safe, nutraceutical supplement, Prodovite VMP35, was developed and assessed in a clinical setting to demonstrate its efficacy in hemoglobin restoration in CAS. Methods A pilot clinical study was conducted to evaluate the safety and efficacy of Prodovite in 38 subjects (men = 10; women = 28; age: 12–82 years). Subjects consumed either placebo or VMP35 (30 ml) and the efficacy was assessed over a period of 0-, 5- or 30 min post-treatment. The safety, rate of absorption and the efficacy of Prodovite was assessed on diverse blood parameters. Changes in peripheral blood smears from 38 subjects were observed using live blood cell imaging (LBCI) with phase contrast microscopy. Adverse events were rigorously monitored. Results Prodovite exhibited positive changes in the blood including morphological, hematological (including restoration of hemoglobin) and rheological changes following 5 min of administration, which were sustained for at least 30 min. Benefits were also observed in subjects with compromised digestive systems. Conclusions Overall, iron free Prodovite VMP35, significantly improved blood morphology and restoration of hemoglobin in these subjects. No adverse events were reported. Funding Sources The Study was funded by Victory Nutrition Inc., Lederach, PA.
Background: Conventional medical therapies for neurodegenerative diseases primarily target anti-inflammatory interventions, immune suppression of autoimmune pathologies, and, depending on the diagnosed pathological mechanisms, neurotransmitter reuptake inhibition, among other tactics. However, the incidence of neuroinflammatory pathologies appears to be progressively increasing. The National Institutes of Health, National Institute of Environmental Health Sciences in 2016, estimated that 5.4 million Americans were living with Alzheimer's. If no effective solutions are found and implemented, within 30 years of this publication, according to data from Harvard, more than 12 million Americans will suffer from neurodegenerative diseases. Methods: Rather than investigating greater etiological depth, modern medicine seems to have been designed to addressing obvious symptomologies to relieve suffering for as long as possible until neuropathological progress inevitably wins in achieving complete functional disability and death. Researchers are reporting herein evidence-based effective treatment therapies that are outside conventional medical standard of care therapies. Conclusion: These therapies are the result of a deeper exploration into etiological factors, including an expanded understanding of the role of anaerobic pathologies in the etiology of neuroinflammatory disorders and methods of reverting to a competent aerobic metabolism. Such therapies include a liquid VMP35 MNC; a greater focus on viral mechanistic pathologies and their remission; and understanding of the genetic basis for a loss of neurological interconnectivity and consequential reward deficiencies in combination with neuronutrient deficiencies, enabling neuronutrient repletion with nutrigenomic therapies such as the KB220Z.
Curculigo orchioides Gaertn (family Hypoxidaceae, also known as black or kali musli), is an endangered medicinal plant used for diverse medicinal purposes including impotency, aphrodisiac, tonic, jaundice, and skin ailments. phytochemical investigations of rhizomes revealed the presence of a novel phenolic glycoside, curculigoside, triterpenoid, saponins, flavones, cellulose, hemicellulose, and calcium oxalate. We developed a novel extract of Curculigo orchioides (commercially known as Blamus™) and assessed its dose‐dependent efficacy (0‐, 10‐, 25‐ and 50 mg/kg body weight p.o.) in male rats (200–230 grams; n = 6) over a period of 28 days. Dose‐ and time‐dependent efficacy of Blamus™ was evaluated on body weight, serum free and total testosterone levels. Furthermore, extensive histopathological analyses and blood chemistry analyses were performed to assess the liver function (SGOT and SGPT), kidney function (BUN) and heart function (creatinine) as the beginning and end of the study. Blamus™ didn't cause any marked elevation in serum free testosterone levels at either10‐ or 25 mg/kg body weight doses, however, a 50 mg/kg body weight dose of Blamus showed a significant increase in serum free testosterone level (*p < 0.0001). However, no significant increases were observed in serum total testosterone levels at 0‐, 10‐, 25‐ or 50 mg/kg body weight doses of Blamus™. No significant changes were observed in serum SGOT, SGPT, BUN and CK levels following treatment with either 0‐, 10‐, 25‐ or 50 mg/kg body weight doses of Blamus™, which demonstrated its broad spectrum safety. Histopathological analyses including investigations on the seminiferous tubules, spermatogenesis, sperm cell morphology, Leydig cells and Sertoli cells following treatment with either 0‐, 10‐, 25‐ or 50 mg/kg body weight doses of Blamus™ demonstrated dose‐dependent improvement in structural integrity. These data demonstrated that Blamus™ may serve as a safe and novel, natural testosterone booster and provide broad spectrum application is sports nutrition, muscle building and exercise pathophysiology.Support or Funding InformationThis project was funded by Cepham Inc, Piscataway, NJ
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.